Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
← catalyst calendarNCT07704099 · readout in 1,063 d
Sponsored by Keros Therapeutics, Inc. (industry) · KROS — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
36estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-14 | estimated | When the study began enrolling |
| Primary completion | 2029-07-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Intervention
- Drug: KER-065 — also filed as Rinvatercept
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs)
measured Up to approximately 14 months
Permalink · KROS's whole pipeline · Catalyst calendar · Every registered study · What changed